CI

At a glance

ClinicalIndex Comparison Record
Phase 1Active· 29 enrolled
Drug / intervention
M032 (NSC 733972)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02062827
NCT02062827Phase 1Active
CompareCT.gov

A Phase 1 Study of M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL-12, in Patients With Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma

University of Alabama at Birmingham·interventional·Posted Feb 14, 2014·Updated Oct 2, 2025

In Brief

A Phase 1 clinical trial evaluating M032 (NSC 733972) for Recurrent Glioblastoma Multiforme and 2 related conditions. Active but no longer recruiting, targeting 29 participants across 1 site.

Detailed Summary

To determine the safety and tolerability of the maximum dose for laboratory engineered Herpes Simplex Virus-1 in patients who would not be eligible for surgical resection of recurrent glioma To determine the safety and tolerability of the maximum dose for laboratory engineered Herpes Simples Virus-1 in patients who would benefit from surgical resection of recurrent glioma

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Glioblastoma Multiforme, Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma or Gliosarcoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 1Active
201420152016201720182019202020212022202320242025202620272028
First PostedFeb 14, 2014
Enrollment StartNov 25, 2013
Primary CompletionSep 1, 2022
Study CompletionSep 1, 2027
TodayJul 2, 2026
Enrollment to primary: 8.8 yearsPosted 12.4 years ago

Interventions

M032 (NSC 733972)biological

A single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI